Dateline Resources to Present at the Australian Rare Earths & Critical Minerals Virtual Investor Conference November 19th

(ASX – Trade24:DTR.AX),(OTCQB:DTREF),(Boerse Frankfurt – Freiverkehr:YE1), SAN BERNARDINO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) — Dateline Resources Limited (ASX:DTR)(OTCQB:DTREF)(FSE:YE1), today announced that Mr Stephen Baghdadi, Dateline's Managing Director will present at the Australian Rare Earths & Critical Minerals Virtual Investor hosted by VirtualInvestorConferences.com, on November 19th, 2025 DATE: November 19th TIME: 3:30 PM ETLINK: REGISTER […]

Sophos Integrates Advanced Cyber Intelligence into Microsoft Security Copilot and Microsoft 365 Copilot

OXFORD, United Kingdom, Nov. 18, 2025 (GLOBE NEWSWIRE) — Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced the general availability of new integrations that connect Sophos Intelix, its robust repository of cyber threat intelligence, with Microsoft Security Copilot and Microsoft 365 Copilot. Introduced at the Microsoft Ignite Conference in San

Sophos Recognized with Microsoft Verified Small and Medium Business (SMB) Solution Status

OXFORD, United Kingdom, Nov. 18, 2025 (GLOBE NEWSWIRE) — Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced its integration with Microsoft Defender for Business, Microsoft Defender for Endpoint, and that its Sophos MDR for Microsoft environments solution has achieved Microsoft verified Small & Medium Business (SMB) solution status through the

Genmab Announces EPKINLY(R) (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

(Copenhagen:GMAB),(LSE:0MGB), Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma in the second-line setting In the Phase 3 EPCORE(R) FL-1 trial, fixed duration EPKINLY + R2 demonstrated significantly superior progression-free survival and overall response rates compared to standard of care

Sophos Integrates Advanced Cyber Intelligence into Microsoft Security Copilot and Microsoft 365 Copilot

Sophos Integrates Advanced Cyber Intelligence into Microsoft Security Copilot and Microsoft 365 Copilot Helping Small Businesses and Global Enterprises Strengthen Defenses with Agentic AI and Sophos Intelix Intelligence to Microsoft Security Copilot and Microsoft 365 Copilot GlobeNewswire November 18, 2025 OXFORD, United Kingdom, Nov. 18, 2025 (GLOBE NEWSWIRE) — Sophos, a global leader of innovative

[Latest] Global Healthcare Command Centers Market Size/Share Worth USD 5.60 Billion by 2034 at a 11.03% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

[Latest] Global Healthcare Command Centers Market Size/Share Worth USD 5.60 Billion by 2034 at a 11.03% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Healthcare Command Centers

Genmab Announces EPKINLY(R) (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma

Genmab Announces EPKINLY(R) (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma GlobeNewswire November 18, 2025 Company Announcement EPKINLY plus rituximab and lenalidomide (EPKINLY + R2) is the first and only bispecific-based therapy approved by the FDA for follicular lymphoma

Sophos Recognized with Microsoft Verified Small and Medium Business (SMB) Solution Status

Sophos Recognized with Microsoft Verified Small and Medium Business (SMB) Solution Status GlobeNewswire November 18, 2025 OXFORD, United Kingdom, Nov. 18, 2025 (GLOBE NEWSWIRE) — Sophos, a global leader of innovative security solutions for defeating cyberattacks, today announced its integration with Microsoft Defender for Business, Microsoft Defender for Endpoint, and that its Sophos MDR for

YieldMax(R) Launches New Fund Family Focused on Growth + Income: Performance and Distribution Target 25(TM) ETFs

YieldMax(R) Launches New Fund Family Focused on Growth + Income: Performance and Distribution Target 25(TM) ETFs GlobeNewswire November 18, 2025 CHICAGO and MILWAUKEE and NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) — YieldMax(R) ETFs is thrilled to announce the expansion of its growth and income fund lineup with the launch of a new fund family:

Inspire Medical Systems, Inc. (INSP) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of January 5, 2026 Deadline

NEW YORK, NY / ACCESS Newswire / November 18, 2025 / If you suffered a loss on your Inspire Medical Systems, Inc. (NYSE:INSP) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/inspire-medical-systems-inc-lawsuit-submission-form?prid=177965&wire=1&utm_campaign=1 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com

Scroll to Top